Investing.com - Myriad Genetics reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Myriad Genetics announced earnings per share of $-0.19 on revenue of $156.4M. Analysts polled by Investing.com anticipated EPS of $-0.06 on revenue of $170.58M.
Myriad Genetics shares are down 24% from the beginning of the year and are trading at $20.74 , down-from-52-week-high.
Myriad Genetics follows other major Healthcare sector earnings this month
Myriad Genetics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar